Dabigatran etexilate is the prodrug of the active moiety dabigatran. Dabigatran etexilate has been shown to have slight, but significant drug-drug interactions when used in combination with strong P-glycoprotein inducers or inhibitors such as amiodarone (sc-291891) or rifampicin (sc-200910). It has also been associated with lower rates of stroke and systemic embolism than warfarin (sc-205888), a comparable anticoagulant. Dabigatran etexilate is an inhibitor of Prothrombin.
1. Verma, A.K. 2010. Med. J. Aust. 192(7): 407-412. PMID: 2036759
2. Walenga, J.M. and Adiguzel, C. 2010. Int. J. Clin. Pract. 64(7): 956-967. PMID: 20584229
3. Maegdefessel, L. et al. 2010. Vasc Health Risk Manag. 6 : 339-349. PMID: 20531953
See how others have used Dabigatran etexilate (CAS 211915-06-9). Click on the entry to view the PubMed entry .
PMID: # 28184906 Warkus, ELL. et al. 2017. Toxicol. Sci. 157: 235-245.
PMID: # 31711903 Reprod. Toxicol.